jamaica
05-12-2010, 09:41 AM
Wed May 12, 2010 7:46am EDT
Stocks
http://www.reuters.com/article/idCNSGE64B0GC20100512?rpc=44
* Phase 2 median survival 18.8 months
* Says data favorable against other studies
May 12 (Reuters) - Vical Inc (VICL.O (http://www.reuters.com/finance/stocks/overview?symbol=VICL.O)) reported positive data from a mid-stage trial of its experimental treatment for metastatic melanoma, a potentially fatal type of skin cancer.
The drug, Allovectin-7, is currently in a late-stage trial through a Special Protocol Assessment agreement with the U.S. Food and Drug Administration.
The company said a mid-stage trial of the drug has found that patients who received high-dose Allovectin-7 had a median survival of 18.8 months.
"These data compare favorably against historical controls from other studies in metastatic melanoma," Vical said.
The mid-stage trial was a single-arm study in which 127 patients were treated with the drug.
Shares of the company closed at $3.37 Tuesday on Nasdaq. (Reporting by Anand Basu in Bangalore; Editing by Vinu Pilakkott)
Stocks
http://www.reuters.com/article/idCNSGE64B0GC20100512?rpc=44
* Phase 2 median survival 18.8 months
* Says data favorable against other studies
May 12 (Reuters) - Vical Inc (VICL.O (http://www.reuters.com/finance/stocks/overview?symbol=VICL.O)) reported positive data from a mid-stage trial of its experimental treatment for metastatic melanoma, a potentially fatal type of skin cancer.
The drug, Allovectin-7, is currently in a late-stage trial through a Special Protocol Assessment agreement with the U.S. Food and Drug Administration.
The company said a mid-stage trial of the drug has found that patients who received high-dose Allovectin-7 had a median survival of 18.8 months.
"These data compare favorably against historical controls from other studies in metastatic melanoma," Vical said.
The mid-stage trial was a single-arm study in which 127 patients were treated with the drug.
Shares of the company closed at $3.37 Tuesday on Nasdaq. (Reporting by Anand Basu in Bangalore; Editing by Vinu Pilakkott)